What is Day Zero Diagnostics?
Headquartered in Boston, Day Zero Diagnostics is a pioneering force in the medical technology sector, specifically targeting the global crisis of antibiotic resistance. By integrating advanced whole-genome sequencing with sophisticated machine learning algorithms, the company provides a diagnostic framework that identifies both the pathogen species and its specific antibiotic resistance profile with unprecedented speed. This approach effectively bypasses the traditional, time-consuming culture-based methods that have long hindered effective clinical intervention. The company's technology not only enhances individual patient care but also provides critical data-driven insights for managing healthcare-associated infection outbreaks, positioning it as an essential partner for modern hospital systems and clinical laboratories.
How much funding has Day Zero Diagnostics raised?
Day Zero Diagnostics has raised a total of $55.3M across 6 funding rounds:
Angel/Seed
$3M
Series A
$8.6M
Corporate Investment
$6.2M
Debt
$467K
Unspecified
$21M
Other Financing Round
$16M
Angel/Seed (2017): $3M with participation from Sands Capital and Golden Seeds
Series A (2019): $8.6M, investors not publicly disclosed
Corporate Investment (2020): $6.2M supported by Carb-X
Debt (2021): $467K featuring PPP
Unspecified (2022): $21M backed by Panacea Ventures, Hongkou Capital, Golden Seeds, Sands Capital, BD, and Triventures
Other Financing Round (2023): $16M, investors not publicly disclosed
Key Investors in Day Zero Diagnostics
Carb-X
CARB-X is a global non-profit partnership dedicated to accelerating antibacterial innovation by funding the development of new antibiotics and rapid diagnostic technologies.
Panacea Ventures
Panacea Ventures is a global healthcare venture fund focused on driving innovation in the biotech sector, with a specific emphasis on life sciences and next-generation therapeutic modalities.
Triventures
Triventures is a global venture capital firm that invests in early-stage companies with innovative breakthroughs in healthcare, focusing on bio-convergence and data-driven technologies.
What's next for Day Zero Diagnostics?
With the recent influx of $16M, Day Zero Diagnostics is poised to transition from its current development and validation phase into broader commercial deployment. The strategic focus will likely center on scaling its diagnostic infrastructure and expanding its footprint within major clinical networks. As the company continues to refine its machine learning models, the integration of its technology into standard hospital workflows will be a primary objective. Furthermore, the firm is expected to leverage its robust investor network to navigate the complexities of global market entry, ensuring that its life-saving diagnostic tools reach the clinical environments where they are most needed to combat the escalating threat of antimicrobial resistance.
See full Day Zero Diagnostics company page
